MARY VEAZEY: Open Payments
NPI 1841832839 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,504 in 76 payments from 19 companies in 2025. Trend: 2023 $1,646 · 2024 $1,939 · 2025 $1,504
Food & beverage: $1,504
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 8 | $257 |
| Lilly USA, LLC | 13 | $240 |
| ABBVIE INC. | 10 | $167 |
| Regeneron Healthcare Solutions, Inc. | 4 | $97 |
| Aimmune Therapeutics, Inc. | 6 | $93 |
| GENZYME CORPORATION | 4 | $86 |
| Intercept Pharmaceuticals, Inc. | 4 | $70 |
| Celltrion USA Inc. | 4 | $69 |
| Ardelyx, Inc. | 3 | $68 |
| Madrigal Pharmaceuticals | 3 | $63 |
Products named: TREMFYA, OMVOH, DUPIXENT, ZENPEP, OCALIVA, VEGZELMA, IBSRELA, REZDIFFRA.
Industry payments across AL — which companies pay providers there.
